Daily Roundup

Ramelius Resources is maintaining its momentum in gold production, reporting 48,839 ounces for the September quarter at an all-in sustaining cost of A$2,656 per ounce. The miner's cash position strengthened considerably, reaching A$768 million following the completion of its Edna May asset sale for A$300 million—a deal that saw the company pocket A$210 million in cash alongside A$90 million in Forrestania shares. Operating cash flow came in at A$186 million for the quarter. Despite weather interruptions that built up stockpiles, Ramelius remains on track to hit its full-year guidance of 205,000 to 225,000 ounces at an AISC between A$2,150 and A$2,350 per ounce. The company is systematically derisking its business plan with ambitions to become a 600,000 ounce producer by FY30, bolstered by key milestones including the award of an EPC contract for its Mt Magnet plant upgrade and EPA approval for the Roe site.

Pureprofile is firing on all cylinders with record quarterly revenue of $18.3 million, up 14% year-on-year, while EBITDA surged 27% to $2.4 million—a particularly impressive feat that shows the company is expanding margins faster than it's growing the top line. The real standout was platform revenue, which more than doubled to $8.8 million and now represents nearly half of total revenue. ANZ operations grew 21% to $9.6 million, while Rest of World revenue climbed 7% to $8.7 million. The company's rolling 12-month annuity revenue hit $16.9 million, and it now works with over 1,000 clients globally. To cap things off, Pureprofile extended its $2.5 million CBA loan facility through November 2029 on improved commercial terms. For the full year, the company is guiding for revenue between $72 million and $75 million with an EBITDA margin of 11% to 12%.

Artrya, the Australian medical technology company, is making serious inroads into the U.S. market. The company signed a five-year commercial agreement with Huntsville Hospital Health System, its largest customer to date, which also became the first SAPPHIRE study participant to convert to full commercial use. Artrya also saw material increases in Salix® Coronary Plaque utilization following the implementation of a pre-authorization workflow at Tanner Health. The company strengthened its Board and executive leadership during the quarter and was included in the S&P/ASX 300 Index, a recognition of its growing stature in the market.

Mach7 Technologies has hit a major milestone—the company posted its first positive operating cash flow in its history, generating A$0.3 million in Q1 FY27. More impressively, this marks the fourth consecutive quarter of positive operating cash flow. The medical imaging software company increased its R&D investment to support product innovation and is sitting pretty with A$19.3 million in cash and no debt. Annual Recurring Revenue came in at A$23.5 million, up 8.5% in constant currency compared to the prior year. The company is gearing up to showcase its next-generation Flamingo portfolio at RSNA 2026, aiming to expand its addressable market and drive future growth.

Invex Therapeutics is making a strategic move into demyelinating diseases through the acquisition of Rekover Therapeutics, a New Zealand biotech company. The all-scrip deal will see Invex hand over 45 million shares and 91.25 million performance rights—with no cash changing hands upfront. Performance rights will vest on the achievement of key milestones. Invex is raising $10 million through a combination of committed and proposed share placements to fund the REVIVE Study and support its existing Exenatide assets. The transaction is subject to shareholder approval and customary conditions.